Effects of estrogen-only therapy on LDL oxidation in women with hysterectomy: Does paraoxonase genotype play a role?

Maturitas

Volumn 53, Issue 3, 2006, Pages 325-332

  Akçay, Yasemin D ^a   Sagin, Ferhan G ^a   Şendaǧ, Fatih ^a   Oztekin, Kemal ^a   Sozmen, Eser Y ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Antioxidant; Atherosclerosis; Estrogen; Hormone replacement therapy; LDL oxidation; PON activity; PON genotype; Surgical menopause

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE 1; CATALASE; CONJUGATED ESTROGEN; COPPER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

ADULT; ALLELE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME POLYMORPHISM; ERYTHROCYTE; FEMALE; GENOTYPE; HUMAN; HYSTERECTOMY; LIPID OXIDATION; MALIGNANT NEOPLASTIC DISEASE; MENOPAUSAL SYNDROME; OVARIECTOMY; POLYMERASE CHAIN REACTION; RESTRICTION MAPPING; SERUM;

ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CATALASE; CHOLESTEROL, LDL; ERYTHROCYTES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; GENOTYPE; HUMANS; HYSTERECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIECTOMY; OXIDATION-REDUCTION; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EQUIDAE;

EID: 31544479774     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2005.05.017     Document Type: Article

References (26)

1. H.L. Li, D.P. Liu, and C.C. Liang Paraoxonase gene polymorphisms, oxidative stress and disease J Mol Med 81 2003 766 779
2. B. Mackness, P.N. Durrington, and M.I. Mackness The paraoxonase gene family and coronary heart disease Curr Opin Lipidol 13 2002 357 362
3. M.I. Mackness, B. Mackness, and P.N. Durrington Paraoxonase and coronary heart disease Athersclerosis Suppl 3 2002 49 55
4. R.A. Hegele Paraoxonase genes and disease Ann Med 31 1999 217 224
5. N. Watzinger, H. Schmidt, and M. Schumacher Human PON1 gene polymorphisms and the risk of coronary heart disease: a community based study Cardiology 98 2002 116 122
6. M.J. Stampfer, and G.A. Colditz Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence Prev Med 20 1991 47 63
7. J. McManus, J. McEneny, I.S. Young, and W. Thompson The effect of various oestrogens and progestogens on the susceptibility of low density lipoproteins to oxidation in vitro Maturitas 25 1996 125 131
8. S. Oparil, and T. Tolbert Cardiovascular effects of estrogen Am J Hypertens 14 2001 186S 193S
9. M.J. Tikkanen, V. Vihma, M. Jauhiainen, A. Hockerstedt, H. Helisten, and M. Kaamanen Lipoprotein-associated estrogens Cardiovasc Res 56 2002 184 188
10. S. Hulley, D. Grady, and T. Bush Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group JAMA 280 1998 605 613
11. J.E. Rossouw, G.L. Anderson, and R.L. Prentice Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
12. K.E. Malterud, T.Y. Farbrot, A.E. Huse, and R.B. Sund Antioxidant and radical scavenging effects of anthraquinones and anthrones Pharmacology 47 1993 7785
13. M.I. Mackness, D. Harty, and D. Bhatnagar Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus Atherosclerosis 86 1991 193 199
14. E.Y. Sözmen, B. Sözmen, and F.K. Girgin Antioxidant enzymes and paraoxonase show co-activity in preserving LDL from oxidation J Lab Clin Med 1 2001 195 199
15. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with folin phenol reagent J Biol Chem 193 1951 265 275
16. R. Humbert, D.A. Adler, C.M. Disteche, C. Hassett, C.J. Omiecinski, and C.E. Furlong The molecular basis of the human serum paraoxonase activity polymorphism Nat Genet 3 1993 73 76
17. Writing Group for the Women's Health Initiative (WHI) Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women JAMA 288 2002 321 333
18. G.T. Shwaery, J.A. Vita, and J.F. Keaney Antioxidant protection of LDL by physiologic concentrations of estrogens is specific for 17 beta-estradiol Atherosclerosis 138 1998 255 262
19. P. Deegan, D. Owens, P. Collins, A. Johnson, and G.H. Tomkin Low-density lipoprotein cholesterol esterification and its relationship with LDL turnover in diabetes Atherosclerosis 112 2 1995 267
20. B. Ruiz-Larrea, A. Leal, C. Martín, R. Martínez, and M. Lacort Effects of estrogens on the redox chemistry of iron: a possible mechanism of the antioxidant action of estrogens Steroids 60 11 1995 780 783
21. J.J. Cho, P. Cadet, E. Salamon, K.J. Mantione, and G.B. Stefano The nongenomic protective effects of estrogen on the male cardiovascular system: clinical and therapeutic implications in aging men Med Sci Monit 9 3 2003 63 68
22. M.I. Mackness, S. Arrol, and B. Mackness Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation Lancet 349 1997 851 852
23. N. Ferre, M. Tous, and A. Paul Paraoxonase Gln-Srg (192) and Leu-Met (55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease Clin Biochem 35 2002 197 203
24. B. Mackness, P. Durrington, and P. McElduff Low paraoxonase activity predicts coronary events in the caerphilly prospective study Circulation 107 2003 2275 2279
25. A.S. Aynacioglu, and Y. Kepekci The human paraoxonase Gln-Arg192 (Q/R) polymorphism in Turkish patients with coronary artery disease Int J Cardiol 74 1 2000 33 37
26. R. Scacchi, R.M. Corbo, and O. Rickards New data on the world distribution of paraoxonase (PON1 Gln192 → Arg) gene frequencies Hum Biol 75 3 2003 365 373